

Supplementary Online Content

Sparano JA., Gray RJ, Makower DF, et al. Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26-100 Assigned to Adjuvant Chemotherapy plus Endocrine Therapy: A Secondary Analysis of the Prospective TAILORx Trial. JAMA Oncology 2019

eTable 1. Chemotherapy regimens

eTable 2. Number and type of events

eTable 3. Nine-year event rates

eFigure 1. Duration of followup by treatment arm

eTable 1. Chemotherapy regimens

Regimen Name	Regimen Dose/Schedule	Regimen Schedule	No. of Cycles
Oral CMF	C 100 mg/m ² /day PO x 14 days M 40 mg/m ² IV days 1, 8 F 600 mg/m ² IV days 1, 8	Every 4 weeks	6
IV CMF	C 600 mg/m ² IV M 40 mg/m ² IV F 600 mg/m ² IV	Every 3 weeks	6-8
Standard AC	A 60 mg/m ² IV C 600 mg/m ² IV	Every 3 weeks	4
Dose dense AC	A 60 mg/m ² IV C 600 mg/m ² IV Plus G-CSF	Every 2 weeks	4
Standard AC - T	A 60 mg/m ² and C 600 mg/m ² IV every 3 weeks x 4 cycles ⇒ T 175 mg/m ² every 3 weeks x 4 cycles	Every 3 weeks	8
Dose dense AC - T	A 60 mg/m ² and C 600 mg/m ² IV plus G-CSF every 2 weeks x 4 cycles ⇒ T 175 mg/m ² plus G-CSF every 2 weeks x 4 cycles	Every 2 weeks	8
FEC	F – 500 mg/m ² IV E – 50-100 mg/m ² IV C – 500 mg/m ² IV	Every 3 weeks	6
TAC	T - 75 mg/m ² A - 50 mg/m ² C - 500 mg/m ² NOTE: TAC should be used only in women ≤ 70 years of age	Every 3 weeks	4-6
TC	T - 75 mg/m ² C - 600 mg/m ²	Every 3 weeks	4
Other protocol-specified regimens	Participating in other CTSU trials including chemotherapy	As specified in protocol	As specified in protocol

eTable 2. Number and type of events in the RS 26-100 cohort at the time of analysis.

Entire followup period

Study Arm	Taxane & Cyclophosphamide	Anthracycline without Taxane	Anthracycline and Taxane	CMF	Other	No chemo therapy	All patients
Number	589	334	244	52	81	89	1389
IBTR	12	5	1	2	0	4	24
Other LR +/- IBTR	17	15	6	3	0	6	47
Distant recurrence +/- other	42	33	12	5	3	6	101
Any recurrence	51	41	14	5	3	12	126
Opposite breast	4	2	2	2	0	0	10
Other second primary	17	11	10	1	5	4	48
Death	34	21	11	4	3	7	80
Any iDFS event	73	55	29	7	8	17	189

Truncated at 5 years

Study Arm	Taxane & Cyclophosphamide	Anthracycline without Taxane	Anthracycline and Taxane	CMF	Other	No chemo therapy	All patients
Number	589	334	244	52	81	89	1389
IBTR	11	4	1	2	0	4	22
Other LR +/- IBTR	16	12	6	3	0	6	43
Distant recurrence +/- other	35	22	10	5	3	5	80
Any recurrence	44	29	13	5	3	11	105
Opposite breast	2	1	1	2	0	0	6
Other second primary	11	7	7	1	3	2	31
Death	21	10	6	4	2	6	49
Any iDFS event	57	36	23	7	6	14	134

eTable 3. Kaplan-Meier estimates of clinical outcomes at 9 years for patients with a RS 26-100 assigned to chemotherapy stratified by adjuvant chemotherapy regimen in the intention-to-treat population. Nine-year Kaplan Meier estimates (percent), standard error, and 95% confidence intervals shown.

Study Arm	All patients	Taxane and Cyclophosphamide	Anthracycline without Taxane	Anthracycline and Taxane	CMF	Other	No therapy
	1389	589	334	244	52	81	89
Invasive disease free survival	75.7 (2.2) (71.1, 79.7)	78.6 (3) (72,83.9)	73.4 (3.7) (65.3,79.9)	77.9 (5.5) (64.7,86.7)	84 (5.6) (69.3,92.1)	66.9 (16.3) (26.9,88.5)	70.5 (6.6) (55.3,81.4)
Freedom from recurrence of breast cancer at a distant site	86.8 (1.7) (83.1, 89.8)	88.3 (2.1) (83.6,91.8)	82.3 (3.4) (74.4,87.9)	92 (2.7) (84.9,95.9)	88.5 (4.8) (74.6,95.1)	95.5 (2.5) (86.8,98.5)	89.3 (4.6) (75.9,95.4)
Freedom from recurrence of breast cancer at a distant or local-regional site	84.8 (1.7) (81.1, 87.8)	86.6 (2.1) (81.8,90.2)	79.5 (3.5) (71.7,85.4)	91.6 (2.6) (84.7,95.4)	88.7 (4.8) (74.9,95.1)	95.5 (2.5) (86.8,98.5)	80.5 (5.5) (66.9,88.9)
Overall survival	89.3% (1.4) (86.3, 91.7)	89.3 (2.2) (84.1,92.9)	88.3 (2.7) (81.7,92.6)	90.9 (2.9) (83.1,95.2)	90.1 (4.7) (75.8,96.2)	93.8 (3.8) (80.1,98.2)	87.9 (4.5) (75.7,94.2)

eFigure 1. Distribution of followup by arm, including arm D (RS 26-100 assigned to chemoendocrine therapy), arm C (RS 11-25 assigned to chemoendocrine therapy), arm B (RS 11-25 assigned to endocrine therapy alone), and arm A (RS 0-10 assigned to endocrine therapy).

